866-997-4948(US-Canada Toll Free)

Coronavirus Infection - Pipeline Review H2 2015

Published By :

Global Markets Direct

Published Date : Aug 2015

Category :

Diseases & Conditions

No. of Pages : 62 Pages

CoronavirusInfection - Pipeline Review, H2 2015

Summary

Global Markets Directs, Coronavirus Infection - Pipeline Review, H2 2015, provides an overview of the Coronavirus Infections therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Coronavirus Infection and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Coronavirus Infection Overview 8
Therapeutics Development 9
Pipeline Products for Coronavirus Infection - Overview 9
Pipeline Products for Coronavirus Infection - Comparative Analysis 10
Coronavirus Infection - Therapeutics under Development by Companies 11
Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 13
Coronavirus Infection - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Coronavirus Infection - Products under Development by Companies 17
Coronavirus Infection - Products under Investigation by Universities/Institutes 18
Coronavirus Infection - Companies Involved in Therapeutics Development 19
AstraZeneca Plc 19
Hemispherx Biopharma, Inc. 20
Humabs BioMed SA 21
Inovio Pharmaceuticals, Inc. 22
NanoViricides, Inc. 23
Novavax, Inc. 24
Organic Vaccines 25
Phelix Therapeutics, LLC 26
Coronavirus Infection - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 37
Drug Profiles 40
Cell Therapy for Coronavirus Infection - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
coronavirus vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drugs to Inhibit Cathepsin L for Coronavirus Infections - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
FBR-001 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
INO-4500 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
interferon alfa-n3 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
interferon beta-1a - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LCA-60 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MERS-COV - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MERS-CoV Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Monoclonal Antibody for Coronavirus Infection - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Viral Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SSYA-10001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Coronavirus Infection - Recent Pipeline Updates 54
Coronavirus Infection - Dormant Projects 59
Coronavirus Infection - Product Development Milestones 60
Featured News & Press Releases 60
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables
Number of Products under Development for Coronavirus Infection, H2 2015 9
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Comparative Analysis by Unknown Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Coronavirus Infection - Pipeline by AstraZeneca Plc, H2 2015 19
Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H2 2015 20
Coronavirus Infection - Pipeline by Humabs BioMed SA, H2 2015 21
Coronavirus Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 22
Coronavirus Infection - Pipeline by NanoViricides, Inc., H2 2015 23
Coronavirus Infection - Pipeline by Novavax, Inc., H2 2015 24
Coronavirus Infection - Pipeline by Organic Vaccines, H2 2015 25
Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Number of Products by Stage and Target, H2 2015 30
Number of Products by Stage and Mechanism of Action, H2 2015 33
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 39
Coronavirus Infection Therapeutics - Recent Pipeline Updates, H2 2015 54
Coronavirus Infection - Dormant Projects, H2 2015 59

List of Figures
Number of Products under Development for Coronavirus Infection, H2 2015 9
Number of Products under Development for Coronavirus Infection - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Products, H2 2015 15
Comparative Analysis by Unknown Stage Development, H2 2015 16
Assessment by Monotherapy Products, H2 2015 27
Number of Products by Top 10 Targets, H2 2015 28
Number of Products by Stage and Top 10 Targets, H2 2015 29
Number of Products by Top 10 Mechanism of Actions, H2 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 32
Number of Products by Top 10 Routes of Administration, H2 2015 34
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 35
Number of Products by Top 10 Molecule Types, H2 2015 37
Number of Products by Stage and Top 10 Molecule Types, H2 2015 38

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *